Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10410635 | 0.85 | FFAR4 (0.43) | MAPTL3MBTL1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL2444693 | 0.82 | BRD4 (0.58) | MAPTL3MBTL1RAB9ASMN1; SMN2GAA | |
| SCHEMBL10919602 | 0.81 | MAPT (0.42) | MAOBMAPTL3MBTL1RAB9ASMN1; SMN2 | |
| SCHEMBL2169810 | 0.81 | L3MBTL1 (0.45) | MAOBMAPTL3MBTL1RAB9ASMN1; SMN2 | |
| SCHEMBL30954778 | 0.81 | L3MBTL1 (0.45) | MAOBMAPTL3MBTL1RAB9ASMN1; SMN2 | |
| SCHEMBL10917600 | 0.81 | NR4A2 (0.54) | L3MBTL1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL6812942 | 0.80 | FOLH1 (0.45) | MAPTL3MBTL1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL7610813 | 0.79 | MAOB (0.56) | MAOBMAPTL3MBTL1RAB9ASMN1; SMN2 | |
| SCHEMBL629773 | 0.79 | MEN1 (0.73) | CYP19A1MAPTL3MBTL1SMN1; SMN2GAA | |
| SCHEMBL21141440 | 0.78 | ADRB2 (0.45) | L3MBTL1BRD4FOLH1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963292-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-7700633-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| CN-101326173-A | Thiadiazoles derivant as anti-diabetes agent | NOVARTIS AG (CH) | 2008-12-17 | — | — | CN | disclosed |
| US-20080262050-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262050-A1 | Organic Compounds | PTPRS, PTPRO, PTPRC | CYP19A1 1316/4885MAOB 1091/4885MAPT 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.